Health interventions are usually judged at their best moment such as the final weigh-in or the last test score. The more informative numbers tend to arrive later, after the treatment stops, or from the comparison group that received less of it.

The Synthesis: A systematic review published in the British Medical Journal in January 2026 combined 37 studies that tracked 9,341 adults after they stopped weight loss medication. Participants lost an average of 8.3 kilograms (18 pounds) on medication, compared with 3.2 kilograms (7 pounds) in groups that received behavioral weight management programs. After stopping, they regained 0.4 kilograms a month, a pace projected to return weight to its starting point after 1.7 years.

For semaglutide and tirzepatide, the newer drugs, trial participants lost 12.3 kilograms (27 pounds) more than comparison groups and then regained the difference at 0.8 kilograms a month. No study followed the newer drugs for more than a year after stopping. Only 12 of the 35 randomised trials were judged well conducted, although restricting the analysis to those did not weaken the result. The field is not divided on the direction: the World Health Organization's first guideline on these drugs, issued in December 2025, treats obesity as a chronic disease and conditionally recommends long-term treatment.

The Calibration: What is overestimated is the idea of these drugs as a course with an end date. What is underestimated is how conventional that makes them: blood pressure and cholesterol medicines also work only while they are taken. The averages conceal a minority who keep the weight off, and the review found no evidence that behavioral support offered alongside or after the drugs slowed the rebound.

The Synthesis: The US POINTER trial, published in the Journal of the American Medical Association (JAMA) in 2025, was announced as evidence that lifestyle change protects the aging brain. It randomised 2,111 sedentary US adults aged 60 to 79, all at raised risk of cognitive decline. One group received a structured two-year program with 38 coached meetings and set targets for exercise, diet and cognitive training. The other attended six meetings and received general encouragement.

Composite test scores covering memory, planning and processing speed rose in both groups, by 0.243 units a year in the structured group and 0.213 in the self-guided group, where one unit is the typical spread of scores between participants. The difference of 0.029 units a year was statistically significant but small. The analysis adjusted for improvements that can occur simply through repeated testing. Without an untreated group, however, the trial cannot establish how much of either group's improvement was caused by its program.

The result matches the field: a 2021 Cochrane review of randomised trials found a similarly small benefit on test scores and little or no effect on dementia diagnoses.

The Calibration: The size of the effect is overestimated, and so is what it demonstrates about dementia. Trials of this kind have not shown fewer dementia diagnoses, and this one was not designed to. What is underestimated is the cheaper arm: the less intensive program produced most of the observed improvement in test scores.

The Synthesis: US dietary guidelines released in January 2026 advise limiting highly processed foods. The best experimental evidence addresses a narrower question: whether processing matters once nutrition is held equal.

A randomised trial in Nature Medicine in 2025 gave 55 adults in England with overweight or obesity, nine in 10 of them women, two eight-week diets in random order. Both met the same UK targets for fat, sugar, salt and fiber. One was prepared from basic ingredients. The other was built from ultraprocessed products, meaning industrially formulated foods such as packaged breakfast cereals and ready meals. Among the 50 who provided results, weight fell 2.06% on the minimally processed diet and 1.05% on the ultraprocessed one.

The field remains divided on how to interpret such findings. Earlier in 2025, the UK’s Scientific Advisory Committee on Nutrition concluded that the link between higher consumption of ultraprocessed and processed foods and adverse health outcomes is concerning. However, limitations in the available evidence meant that it was unclear whether these foods are inherently unhealthy due to processing or because a large majority of them are high in calories, saturated fat, salt and/or free sugars.

The Calibration: The claim that processing alone determines whether a diet supports weight loss is too strong. Participants lost weight on both diets when each followed nutritional guidance, although weight loss was greater on the minimally processed diet. The trial suggests that processing may have an effect beyond nutritional composition, but eight weeks in 50 participants cannot establish long-term effects on disease. Nutritional quality remains well supported as a guide to healthy eating; the independent contribution of processing requires further evidence.

Testimonials for supplements, devices and diets share a familiar structure: the symptom was bad, the remedy was tried, the symptom improved. The pattern holds across products with nothing in common, which is a reason for caution more than confidence.

The explanation is statistical: symptoms and measurements fluctuate. For example back pain flares and settles, and blood pressure readings vary. People seek treatment, and researchers enroll participants, at the worst moments: when pain peaks or a reading crosses a threshold. From an extreme, the likeliest next value is a more ordinary one, whether or not anything is done. Statisticians call this regression to the mean, and a standard account in the International Journal of Epidemiology describes it as natural variation that looks like real change. The effect is strongest when measurements are noisy and when people are selected because of an unusually high or low first reading, a pattern common in personal health experiments and uncontrolled studies.

This does not mean a remedy cannot work. It means that improvement after treatment begins is not enough to establish that it did. The most informative comparison is between people receiving an intervention and a comparable group that does not receive it.

The useful habit is to ask what a before-and-after claim is being compared with. An improvement that begins from a bad spell, with nothing to compare it against, may show only that the bad spell ended. An improvement greater than that seen in a comparable group offers stronger evidence that the remedy contributed to the change.

The Claim: Wearing a weighted vest on walks or through the day builds or preserves bone, particularly for women in midlife and after menopause.

The Distortion: A 12-month randomised trial in JAMA Network Open in 2025 assigned 150 older adults with obesity, three-quarters of them women, to a weight-loss program alone, with a vest worn about seven hours a day, or with resistance training. Hip bone density fell by 1.2% to 1.9% in all three groups, with no advantage for the vest.

The Calibration: The trial tested bone loss during dieting, so it does not rule out every benefit, but vests are not an established way to preserve bone.

The Claim: Daily creatine, long sold for muscle, also sharpens memory and thinking.

The Distortion: Trials with mixed results are being presented as an established benefit. In 2024 the European Union’s food safety regulator, the European Food Safety Authority, reviewed the human trials submitted in support of a cognitive claim. It found no consistent effect on memory, attention or other mental skills and concluded that cause and effect had not been established.

The Calibration: The cognitive claim remains a hypothesis under study.

Stay calibrated.

If The Calibration brought you a clearer perspective today, forward it to someone who values the same.

Received this from a friend or colleague? Subscribe here to get it directly.

Weight Regain After Cessation of Medication for Weight Management: Systematic Review and Meta-Analysis. British Medical Journal, 2026.

WHO Guideline on the Use of Glucagon-Like Peptide-1 (GLP-1) Therapies for the Treatment of Obesity in Adults. World Health Organization, 2025.

Structured vs Self-Guided Multidomain Lifestyle Interventions for Global Cognitive Function: The US POINTER Randomized Clinical Trial. The Journal of the American Medical Association, 2025.

Multi-Domain Interventions for the Prevention of Dementia and Cognitive Decline. Cochrane Database of Systematic Reviews, 2021.

Ultraprocessed or Minimally Processed Diets Following Healthy Dietary Guidelines on Weight and Cardiometabolic Health: A Randomized, Crossover Trial. Nature Medicine, 2025.

Dietary Guidelines for Americans, 2025-2030. US Department of Agriculture and US Department of Health and Human Services, 2026.

Processed Foods and Health: SACN’s Rapid Evidence Update. Scientific Advisory Committee on Nutrition, 2025.

Regression to the Mean: What It Is and How to Deal With It. International Journal of Epidemiology, 2005.

Weighted Vest Use or Resistance Exercise to Offset Weight Loss–Associated Bone Loss in Older Adults: A Randomized Clinical Trial. JAMA Network Open, 2025.

Creatine and Improvement in Cognitive Function: Evaluation of a Health Claim Pursuant to Article 13(5) of Regulation (EC) No 1924/2006. EFSA Journal, 2024.

The Calibration is an editorially curated health briefing. Content is drawn from published research and credible sources for informational purposes only. It does not constitute medical advice, clinical guidance, diagnosis, or treatment, and is not a substitute for consultation with a qualified healthcare professional. Nothing in this briefing should be used to make health or treatment decisions or to delay seeking professional medical advice.

Sponsored content, when present, will always be clearly identified.